trial

A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)

NCTId NCT00212797
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 273 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2006-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
273 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2004-07
Primary completion
2006-07
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Org 34517

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjuncti — primary completion2006-07

Facts & assertions

4 sourced
Enrollment
273
Phase
PHASE2
Primary Completion Date
2006-07
Status
COMPLETED
relationships
The graph out of here
drug
Org 34517
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Psychotic Disorders
indication
Depression
indication
Psychotic Disorders
indication